University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK; Institute of Microbiology and Infection, The University of Birmingham, Edgbaston, Birmingham, UK.
J Hosp Infect. 2019 Jun;102(2):165-167. doi: 10.1016/j.jhin.2018.12.018. Epub 2019 Jan 4.
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
非达霉素是一种用于治疗艰难梭菌感染（CDI）的大环内酯类抗生素。在英国，非达霉素通常保留用于治疗严重的 CDI 或复发。在伯明翰伊丽莎白女王医院，对 2017/2018 年所有疗程的非达霉素进行了审查。38 名患者接受了非达霉素治疗，在轻度 CDI 的首次发作时给予非达霉素治疗时，64%的患者对治疗有反应。相反，所有复发性 CDI 患者的非达霉素治疗均失败。对于严重 CDI 使用非达霉素的结果喜忧参半，只有 42%的患者有反应。这些结果表明，非达霉素最适合作为患者首次发作时轻度 CDI 的治疗药物。
